Rapport Therapeutics
Update in progressRAPP (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative small molecule medicines for CNS disorders. Its lead candidate, RAP-219, targets TARPy8-containing AMPARs with picomolar affinity for focal epilepsy and other CNS conditions. The company also pursues nicotinic receptor programs (a6 nAChR for chronic pain and migraine; a9a10 nAChR for hearing/vestibular disorders). Formerly Precision Neuroscience NewCo, Inc., it was renamed in 2022 and is based in Boston, MA.
Company score
- Sentiment
- 0.54
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.08
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.28
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!